🚀 VC round data is live in beta, check it out!
BioVersys Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioVersys and similar public comparables like EQL Pharma, Scancell, Tiziana Life Sciences, Orthocell and more.
BioVersys Overview
About BioVersys
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The company focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others.
Founded
2010
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$88M
BioVersys Financials
BioVersys reported last 12-month revenue of $4M and negative EBITDA of ($35M).
In the same LTM period, BioVersys generated $4M in gross profit, ($35M) in EBITDA losses, and had net loss of ($36M).
Revenue (LTM)
BioVersys P&L
In the most recent fiscal year, BioVersys reported revenue of — and net income of —.
BioVersys expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $4M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($35M) | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (989%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (946%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($36M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (1014%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioVersys Stock Performance
BioVersys has current market cap of $182M, and enterprise value of $88M.
Market Cap Evolution
BioVersys' stock price is $31.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $88M | $182M | (0.2%) | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioVersys Valuation Multiples
BioVersys trades at 24.6x EV/Revenue multiple, and (2.5x) EV/EBITDA.
EV / Revenue (LTM)
BioVersys Financial Valuation Multiples
As of March 7, 2026, BioVersys has market cap of $182M and EV of $88M.
Equity research analysts estimate BioVersys' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioVersys has a P/E ratio of (5.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $182M | XXX | $182M | XXX | XXX | XXX |
| EV (current) | $88M | XXX | $88M | XXX | XXX | XXX |
| EV/Revenue | 24.6x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (2.5x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (2.6x) | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 24.6x | XXX | — | XXX | XXX | XXX |
| P/E | (5.0x) | XXX | — | XXX | XXX | XXX |
| EV/FCF | (2.7x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioVersys Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioVersys Margins & Growth Rates
BioVersys' revenue in the last 12 month grew by 73%.
BioVersys' rule of 40 is (916%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioVersys' rule of X is (807%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BioVersys Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 73% | XXX | 111% | XXX | XXX | XXX |
| EBITDA Margin | (989%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (2%) | XXX | 74% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (916%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (807%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 310% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 711% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioVersys Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| EQL Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Scancell | XXX | XXX | XXX | XXX | XXX | XXX |
| Tiziana Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthocell | XXX | XXX | XXX | XXX | XXX | XXX |
| Cartesian Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioVersys M&A Activity
BioVersys acquired XXX companies to date.
Last acquisition by BioVersys was on XXXXXXXX, XXXXX. BioVersys acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioVersys
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioVersys Investment Activity
BioVersys invested in XXX companies to date.
BioVersys made its latest investment on XXXXXXXX, XXXXX. BioVersys invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioVersys
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioVersys
| When was BioVersys founded? | BioVersys was founded in 2010. |
| Where is BioVersys headquartered? | BioVersys is headquartered in Switzerland. |
| Is BioVersys publicly listed? | Yes, BioVersys is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of BioVersys? | BioVersys trades under BIOV ticker. |
| When did BioVersys go public? | BioVersys went public in 2025. |
| Who are competitors of BioVersys? | BioVersys main competitors are EQL Pharma, Scancell, Tiziana Life Sciences, Orthocell. |
| What is the current market cap of BioVersys? | BioVersys' current market cap is $182M. |
| What is the current revenue of BioVersys? | BioVersys' last 12 months revenue is $4M. |
| What is the current revenue growth of BioVersys? | BioVersys revenue growth (NTM/LTM) is 73%. |
| What is the current EV/Revenue multiple of BioVersys? | Current revenue multiple of BioVersys is 24.6x. |
| Is BioVersys profitable? | No, BioVersys is not profitable. |
| What is the current EBITDA of BioVersys? | BioVersys has negative EBITDA and is not profitable. |
| What is BioVersys' EBITDA margin? | BioVersys' last 12 months EBITDA margin is (989%). |
| What is the current EV/EBITDA multiple of BioVersys? | Current EBITDA multiple of BioVersys is (2.5x). |
| What is the current FCF of BioVersys? | BioVersys' last 12 months FCF is ($33M). |
| What is BioVersys' FCF margin? | BioVersys' last 12 months FCF margin is (914%). |
| What is the current EV/FCF multiple of BioVersys? | Current FCF multiple of BioVersys is (2.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.